TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01772862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors
Study: NCT01860989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 75mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 150mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 225mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: KAE609 300mg single dose
Study: NCT02422758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket
Description: 3M™ Bair Hugger™Preoperative \& Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Prewarming
Study: NCT03680027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut-enriched Group
Description: All subjects supplemented with 40 g/day of walnuts for 6 weeks.
Study: NCT03401957

Intervention type: DRUG
Intervention: Cetuximab
Description: Cetuximab-based infusional 5-FU regimen as the 1st line treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: liquid biopsy
Description: The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
Study: NCT03184272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 1
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Trendelenburg-position (ATB)
Description: measurement under ATB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB in narcosis
Description: measurement under ATB in narcosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 1
Description: measurement in supine position in narcosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising
Description: measurement under passive leg raising

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume bolus substitution
Description: measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline in narcosis 2
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: start capnoperitoneum
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum
Description: measurement under ATB plus capnoperitoneum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB plus capnoperitoneum plus volume bolus substitution
Description: measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATB loss of capnoperitoneum
Description: measurement under ATB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: baseline alert 2
Description: measurement in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the beginning
Description: measurement in the recovery unit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: torso position rising 30° at the end
Description: measurement in the recovery unit
Study: NCT05345080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-Reduction Intervention
Description: The customized exposure-reduction intervention includes a phone-based telehealth visit, collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies (optional), and a customized asthma self-management and exposure-reduction plan developed using motivational interviewing techniques, support, and exposure-reduction supplies.
Study: NCT00836108

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: breathing strategy
Description: Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing strategy
Description: Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing strategy
Description: Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
Study: NCT02804893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS
Description: Thorax thoracoscopic surgery (lobectomy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RATS
Description: Thorax robotic surgery (lobectomy)
Study: NCT01346306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith Company - direct current stimulator
Description: Direct current stimulation montage 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith Company - direct current stimulator
Description: Direct current stimulation montage 2.
Study: NCT03246945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions on taking photographs provided, see methods
Description: Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
Study: NCT01976208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150\~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg\~750mg，then dosing interval is every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04233229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ
Description: closed-loop in patients at home for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home healthcare services
Description: home healthcare services from Air Liquide in patients at home for three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care for daily insulin treatment
Description: multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
Study: NCT01147445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Mutant Heat- Labile Toxin (dmLT)
Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
Study: NCT00678457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron (4 μg/kg b.i.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine (9, 18, and 36 μg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04646629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at ST36 (Zusanli) and ST37 (Shangjuxu) twice a day for seven days.After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at ST36 and ST37(nonacupoints located 1 inch beside acupoints, about20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group
Study: NCT01738958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L. retueri
Description: two tablets a day for 6 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01919853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study: NCT02523209

Intervention type: DEVICE
Intervention: HR-pQCT
Description: HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.

Intervention type: DEVICE
Intervention: DEXA
Description: The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( \<15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
Study: NCT03826615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
Study: NCT03931070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Patients assigned to Ramelteon group will receive 8mg of Ramelteon every night throughout the hospitalization or up to 30 days, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Cap
Description: Patients assigned to Placebo group will receive placebo pill that is indistinguishable from Ramelteon, every night throughout the hospitalization or up to 30 days, whichever is sooner.
Study: NCT02750722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flutter®
Description: Acute exercise with Flutter® breathing therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Flutter®
Description: Acute exercise without Flutter® breathing therapy.
Study: NCT04081181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
Study: NCT04208230

Intervention type: DEVICE
Intervention: XtremeCT
Description: HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.

Intervention type: DEVICE
Intervention: XtremeCT
Description: HRpQCT technology provides information on bone microarchitecture, bone density and bone strength by measuring the cortical and trabecular bone structures with improved spatial resolution and defining the surfaces in three-dimensional manner.
Study: NCT03989544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study: NCT00297401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32 mg, QD, PO, up to 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD, PO, up to 8 weeks
Study: NCT01267578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination
Description: Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
Study: NCT02630030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study: NCT00941343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin (XATRAL® - SL770499)
Description: One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
Study: NCT01584934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Description: Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
Study: NCT01091610

Intervention type: OTHER
Intervention: no intervention
Description: purely observational retrospective study. no interventions are planned.

Intervention type: OTHER
Intervention: no intervention
Description: purely observational retrospective study. no interventions are planned.
Study: NCT01643213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Boston Scientific SCS Trial Therapy
Description: No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSC approved SCS Trial Therapy w/ OMG
Description: No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
Study: NCT04130841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Limiting Membrane Peeling
Description: After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Limiting Membrane Peeling
Description: After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
Study: NCT02353780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
Description: TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept; SQ; specifics to be determined by the treating rheumatologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab; SQ; specifics determined by the treating rheumatologist.
Study: NCT00513214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Study: NCT04199520

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surgery combined with systemic therapy
Description: surgery combined with systemic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy
Description: systemic therapy
Study: NCT02600260

Intervention type: DRUG
Group type: OTHER
Intervention: Enoxaparin
Description: Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Hospitalized patients that score less than three are not prescribed enoxaparin.
Study: NCT01731548

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hyperfractionated radiation therapy for both arms
Description: 1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy for both arms
Description: 1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
Study: NCT00058591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection of EBV specific CTLS
Description: The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals.